Table 1.
Baseline characteristics of patients within each sub-group.
| BB DALK Group | FS DALK Group | Manual DALK Group | Converted Group | Test Value * | p-Value | Sig. | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No | % | |||||
| Gender | Female | 8 | 28.6% | 6 | 40.0% | 14 | 34.1% | 4 | 19.0% | 2.245 | 0.523 | NS |
| Male | 20 | 71.4% | 9 | 60.0% | 27 | 65.9% | 17 | 81.0% | ||||
| Indication for surgery | KC scar | 17 | 60.7% | 3 | 20.0% | 22 | 53.7% | 15 | 71.4% | 10.065 | 0.018 | S |
| HSV scar | 6 | 21.4% | 2 | 13.3% | 6 | 14.6% | 2 | 9.5% | 1.415 | 0.702 | NS | |
| LSCD | 0 | 0.0% | 0 | 0.0% | 4 | 9.8% | 2 | 9.5% | 4.415 | 0.220 | NS | |
| Post LVC ectasia | 1 | 3.6% | 1 | 6.7% | 0 | 0.0% | 0 | 0.0% | 3.441 | 0.328 | NS | |
| Post DALK scar | 0 | 0.0% | 0 | 0.0% | 1 | 2.4% | 0 | 0.0% | 1.576 | 0.665 | NS | |
| Stromal scarring after SALK | 0 | 0.0% | 2 | 13.3% | 0 | 0.0% | 0 | 0.0% | 12.233 | 0.007 | HS | |
| Post infection scar | 0 | 0.0% | 3 | 20.0% | 3 | 7.3% | 1 | 4.8% | 6.529 | 0.089 | NS | |
| Superficial Scarring | 1 | 3.6% | 0 | 0.0% | 1 | 2.4% | 0 | 0.0% | 1.208 | 0.751 | NS | |
| Lattice Dyst | 0 | 0.0% | 2 | 13.3% | 1 | 2.4% | 0 | 0.0% | 7.398 | 0.060 | NS | |
| Post PK ectatic graft | 0 | 0.0% | 1 | 6.7% | 0 | 0.0% | 1 | 4.8% | 4.018 | 0.260 | NS | |
| SJS | 0 | 0.0% | 0 | 0.0% | 1 | 2.4% | 0 | 0.0% | 1.576 | 0.665 | NS | |
| Aniridia | 0 | 0.0% | 0 | 0.0% | 1 | 2.4% | 0 | 0.0% | 1.576 | 0.665 | NS | |
| KG | 0 | 0.0% | 0 | 0.0% | 1 | 2.4% | 0 | 0.0% | 1.576 | 0.665 | NS | |
| Schnyder Dystrophy | 1 | 3.6% | 1 | 6.7% | 0 | 0.0% | 0 | 0.0% | 3.441 | 0.328 | NS | |
| Granular Dystrophy | 1 | 3.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2.776 | 0.427 | NS | |
| Reis Buckler Dystrophy | 1 | 3.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2.776 | 0.427 | NS | |
p-value > 0.05: Non significant (NS); p-value < 0.05: Significant (S); p-value < 0.01: highly significant (HS); *: Chi-square test.